Latest & greatest articles for adhd Methylphenidate

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on adhd Methylphenidate or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on adhd Methylphenidate and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for adhd Methylphenidate

21. Varying the wear time of the methylphenidate transdermal system in children with attention-deficit/hyperactivity disorder (Abstract)

Varying the wear time of the methylphenidate transdermal system in children with attention-deficit/hyperactivity disorder Children with attention-deficit/hyperactivity disorder often have varying needs for coverage of their symptoms throughout the day. The objectives of this study were to determine the efficacy, duration of action, and safety of methylphenidate transdermal system worn for variable times by children (ages 6-12) diagnosed with ADHD.Methylphenidate dose was optimized over 5 weeks (...) using 10-, 15-, 20-, or 30-mg patches worn for 9 hours. The efficacy of 4- and 6-hour wear times was then assessed in an Analog Classroom setting during a randomized, placebo-controlled, double-blind, three-way crossover phase. The main efficacy measures were the Swanson, Kotkin, Agler, M-Flynn, and Pelham Rating Scale deportment scale and the Permanent Product Measure of Performance math test.All of the efficacy measures indicated that 4- and 6-hour wear times improved ADHD symptoms

2008 EvidenceUpdates Controlled trial quality: uncertain

22. Atomoxetine and Osmotically Released Methylphenidate for the Treatment of Attention Deficit Hyperactivity Disorder: Acute Comparison and Differential Response (Abstract)

Atomoxetine and Osmotically Released Methylphenidate for the Treatment of Attention Deficit Hyperactivity Disorder: Acute Comparison and Differential Response Response to atomoxetine, a nonstimulant norepinephrine-specific reuptake inhibitor, was compared with the effect of osmotic-release oral methylphenidate, a long-acting methylphenidate preparation, in patients with attention deficit hyperactivity disorder (ADHD).In a large placebo-controlled, double-blind study, patients ages 6-16 (...) with ADHD, any subtype, were randomly assigned to receive 0.8-1.8 mg/kg per day of atomoxetine (N=222), 18-54 mg/day of osmotically released methylphenidate (N=220), or placebo (N=74) for 6 weeks. The a priori specified primary analysis compared response (at least 40% decrease in ADHD Rating Scale total score) to osmotically released methylphenidate with response to atomoxetine and placebo. After 6 weeks, patients treated with methylphenidate were switched to atomoxetine under double-blind

2008 EvidenceUpdates Controlled trial quality: uncertain

23. Methylphenidate may improve symptoms but does not increase response compared with placebo in preschool children with ADHD

Methylphenidate may improve symptoms but does not increase response compared with placebo in preschool children with ADHD Methylphenidate may improve symptoms but does not increase response compared with placebo in preschool children with ADHD | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using (...) your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Methylphenidate may improve symptoms but does not increase response compared with placebo in preschool children with ADHD Article Text

2008 Evidence-Based Mental Health

24. Long-acting methylphenidate-OROS in youths with attention-deficit hyperactivity disorder suboptimally controlled with immediate-release methylphenidate: a study of cost effectiveness in the Netherlands

and the study was well presented, especially the economic details. The authors’ conclusions appear to be robust. Type of economic evaluation Cost-utility analysis Study objective This study examined the cost-effectiveness of long-acting methylphenidate osmotic release oral system (OROS) for the treatment of young people (8 to 18 years) with attention deficit hyperactivity disorder (ADHD), for whom treatment with immediate-release (IR) methylphenidate was effective, but sub-optimal due to problems (...) . A randomized, controlled, effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention-deficit-hyperactivity-disorder. Can J Clin Pharmacol 2006;13:e50-62. Vanoverbeke N, Annemans L, Ingham M, et al. A cost analysis of the management of attention-deficit/hyperactivity disorder (ADHD) in children in the UK. J Med Economics 2003;6:79-94. Wolraich ML, Greenhill LL, Pelham W, et al. Randomized, controlled trial of oros methylphenidate once a day

2008 NHS Economic Evaluation Database.

25. Methylphenidate may improve symptoms but does not increase response compared with placebo in preschool children with ADHD. (Abstract)

Methylphenidate may improve symptoms but does not increase response compared with placebo in preschool children with ADHD. 17459991 2007 05 22 2007 04 26 1362-0347 10 2 2007 May Evidence-based mental health Evid Based Ment Health Methylphenidate may improve symptoms but does not increase response compared with placebo in preschool children with ADHD. 60 Wolraich Mark L ML OU Child Study Center, Oklahoma City, Oklahoma, USA. eng Comment Journal Article England Evid Based Ment Health 100883413

2007 Evidence-Based Mental Health Controlled trial quality: uncertain

26. Adding multimodal behavioural therapy to methylphenidate does not improve ADHD outcomes

Adding multimodal behavioural therapy to methylphenidate does not improve ADHD outcomes Adding multimodal behavioural therapy to methylphenidate does not improve ADHD outcomes | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Adding multimodal behavioural therapy to methylphenidate does not improve ADHD outcomes Article Text Therapeutics Adding multimodal behavioural therapy to methylphenidate does not improve ADHD outcomes Statistics from

2007 Evidence-Based Mental Health

27. Adding psychosocial therapy to methylphenidate may not improve its effectiveness in stimulant responsive children with ADHD Full Text available with Trip Pro

for ADHD in stimulant responsive children? METHODS Design: Randomised controlled trial. Allocation: Not reported. Blinding: Phase 1 unblinded; phase 2 participants blinded to placebo substitution. Follow up period: 24 months. Setting: Two medical centres, New York and Montreal. Patients: 103 children aged 7–10 years with DSM-III attention deficit/hyperactivity disorder (ADHD) who had previously responded to methylphenidate; ⩾1.5 on hyperactivity index of Conners’ teacher rating scale; medication free (...) Am Child Adolesc Psychiatry 2004 ; 43 : 792 –801. MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 1999 ; 56 : 1073 –86. Footnotes For correspondence: Dr Abikoff, NYU Child Study Centre, 215 Lexington Avenue, 13th Floor, New York, NY 10016, USA Sources of funding: NIMH grant. Request Permissions If you wish to reuse any or all of this article please use the link below which will take you

2006 Evidence-Based Mental Health

28. Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents (TA98)

Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents (TA98) Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents | Guidance | NICE Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents Technology appraisal guidance [TA98] Published date: 22 March 2006 Guidance This guidance has

2006 National Institute for Health and Clinical Excellence - Technology Appraisals

29. A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents

and the authors' conclusions are likely to be reliable. Authors' objectives To assess the clinical and cost-effectiveness of methylphenidate (MPH), dexamfetamine sulfate (DEX) and atomoxetine (ATX) in children and adolescents diagnosed with attention deficit hyperactivity disorder (ADHD). Searching The authors searched ten databases (listed) for published literature; the search strategies used were reported. The searches were conducted in July 2004 and no language restrictions were imposed. Only studies (...) A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents A systematic review and economic model

2006 DARE.

30. Cognitive effects of immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder

and control group were eligible for inclusion. Specific interventions included in the review Studies comparing immediate-release methylphenidate with placebo were eligible for inclusion. The majority of the included studies used a single dose immediate-release methylphenidate that was not varied based on patient characteristics. Participants included in the review Studies of children who met formal diagnostic criteria for ADHD or attention-deficit disorder, or who were described as hyperactive (...) Cognitive effects of immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder Cognitive effects of immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder Cognitive effects of immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder Pietrzak R H, Mollica C M, Maruff P, Snyder P J CRD summary This review assessed the cognitive effects of immediate-release methylphenidate in children

2006 DARE.

31. Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents: review of Technology Appraisal 13

Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents: review of Technology Appraisal 13 Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents: review of Technology Appraisal 13 Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents: review of Technology Appraisal 13 National (...) Institute for Health and Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation National Institute for Health and Clinical Excellence. Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents: review of Technology Appraisal 13. London: National Institute for Health and Clinical Excellence

2006 Health Technology Assessment (HTA) Database.

32. A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents

, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents. Health Technology Assessment 2006; 10(23): 1-162 Authors' objectives

The aim of this document is to assess the clinical and cost-effectiveness of oral methylphenidate hydrochloride (MPH), dexamfetaminesulphate (DEX) and atomoxetine (ATX) in children and adolescents (<18 years of age) diagnosed with attention deficit hyperactivity disorder (ADHD) (including hyperkinetic disorder).

methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents A systematic review and economic model

2006 Health Technology Assessment (HTA) Database.

33. Cost-effectiveness of dexamphetamine and methylphenidate for the treatment of childhood attention deficit hyperactivity disorder

Cost-effectiveness of dexamphetamine and methylphenidate for the treatment of childhood attention deficit hyperactivity disorder Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2004 NHS Economic Evaluation Database.

34. Cost-effectiveness of methylphenidate versus AMP/DEX mixed slats for the first-line treatment of ADHD

, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of methylphenidate (MPH) versus amphetamine/dextroamphetamine mixed salts (AMP/DEX) as first-line agents for the treatment of attention deficit hyperactivity disorder (ADHD) was studied. Type of intervention Treatment. Economic study type Cost-utility analysis. Study population The study population comprised a hypothetical cohort of male children aged (...) in the review No study designs were reported. However, the studies used to assess efficacy rates included those that assessed response to therapy at a minimum of 1 month and a maximum of 8 weeks. Sources searched to identify primary studies HealthSTAR and MEDLINE were searched for primary studies using the keywords "attention deficit hyperactivity disorder", "methylphenidate", "amphetamine / dextroamphetamine mixed salts", "adverse events", "compliance rates", "school administration", "economic burden

2004 NHS Economic Evaluation Database.

35. How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents: a meta-analysis

D Authors' objectives To review the efficacy and safety of short-acting methylphenidate (Ritalin), compared with placebo, for attention-deficit disorder (ADD) in individuals aged 18 years and less. Searching The following sources were searched for a range of dates, the earliest being 1981: MEDLINE, EMBASE, PsycINFO, ERIC, CINAHL, HealthSTAR, Biological Abstracts, Current Contents, and Dissertation Abstracts. There were no restrictions on either the language or publication status of the reports (...) no more than 4 weeks. For all categories of primary diagnosis, and for both informants, statistically-significant methylphenidate effects were observed. Both the HI-T and HI-P estimates for attention-deficit hyperactivity disorder diagnosis studies decreased their initial methylphenidate effect estimates. The strongest teacher and parent effects were seen for ADD with hyperactivity trials, and mixed diagnosis trials, respectively. For teacher data, the magnitude of the methylphenidate effect

2001 DARE.

36. Methylphenidate (Ritalin, Equasym) for attention deficit/hyperactivity disorder (ADHD) in childhood

Methylphenidate (Ritalin, Equasym) for attention deficit/hyperactivity disorder (ADHD) in childhood Methylphenidate (Ritalin, Equasym) for attention deficit/hyperactivity disorder (ADHD) in childhood Methylphenidate (Ritalin, Equasym) for attention deficit/hyperactivity disorder (ADHD) in childhood National Institute for Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made (...) for the HTA database. Citation National Institute for Clinical Excellence. Methylphenidate (Ritalin, Equasym) for attention deficit/hyperactivity disorder (ADHD) in childhood. London: National Institute for Clinical Excellence (NICE). Technology Appraisal Guidance 13. 2000 Authors' objectives To provide guidance on the use of methylphenidate (Ritalin, Equasym) for attention deficit/hyperactivity disorder (ADHD) in childhood. Authors' conclusions Guidance 1.1 Methylphenidate is recommended for use as part

2000 Health Technology Assessment (HTA) Database.